Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02781311 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 169
- Enrollment target
NCT02781311 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 169 participants.
The verdict
NCT02781311, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 169 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).
Interventions
- DRUG Placebo
- DRUG Finasteride
- DRUG Setipiprant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2016-07-14 |
| Est. Completion | 2018-05-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02781311
The ClinicalTrials.gov registry entry for NCT02781311 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02781311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02781311 about?
NCT02781311 is a clinical study titled "A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males". This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).
What is the current status of trial NCT02781311?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 169 participants. The study started on 2016-07-14. Estimated completion is 2018-05-22.
What interventions are being tested in trial NCT02781311?
The interventions under investigation include: Placebo (DRUG), Finasteride (DRUG), Setipiprant (DRUG).
Who is sponsoring clinical trial NCT02781311?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.